OraSure Technologies (NASDAQ:OSUR) Director Buys $74,500.00 in Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) Director Steven Kyle Boyd purchased 25,000 shares of OraSure Technologies stock in a transaction on Tuesday, May 12th. The stock was bought at an average price of $2.98 per share, for a total transaction of $74,500.00. Following the transaction, the director directly owned 63,462 shares in the company, valued at approximately $189,116.76. The trade was a 65.00% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Steven Kyle Boyd also recently made the following trade(s):

• On Thursday, May 14th, Steven Kyle Boyd acquired 25,000 shares of OraSure Technologies stock. The shares were bought at an average price of $2.99 per share, with a total value of $74,750.00.

OraSure Technologies Stock Down 3.0%

OraSure Technologies stock traded down $0.09 during mid-day trading on Thursday, hitting $2.95. 868,088 shares of the stock were exchanged, compared to its average volume of 535,873. The stock has a market capitalization of $203.11 million, a price-to-earnings ratio of -2.84 and a beta of 0.89. OraSure Technologies, Inc. has a 12 month low of $2.08 and a 12 month high of $3.82. The firm’s fifty day simple moving average is $3.06 and its two-hundred day simple moving average is $2.76.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). OraSure Technologies had a negative net margin of 66.42% and a negative return on equity of 18.57%. The firm had revenue of $26.76 million during the quarter, compared to the consensus estimate of $26.44 million.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $3.00.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Quadrature Capital Ltd bought a new position in OraSure Technologies during the fourth quarter worth $28,000. Prudential Financial Inc. bought a new stake in OraSure Technologies during the 2nd quarter worth approximately $31,000. Diversify Wealth Management LLC purchased a new stake in OraSure Technologies in the 1st quarter valued at $36,000. Amundi purchased a new stake in shares of OraSure Technologies in the first quarter valued at about $47,000. Finally, SG Americas Securities LLC increased its stake in OraSure Technologies by 77.7% in the 4th quarter. SG Americas Securities LLC now owns 19,748 shares of the medical instruments supplier’s stock valued at $48,000 after buying an additional 8,632 shares during the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.